Ohio State Navbar

Our Research

Dr. Kevin Hackshaw


Principal Investigator- Kevin Hackshaw, MD

  • LUPUS

    A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI?546 in Subjects with Systemic Lupus Erythematosus MedImmune

    A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab  (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus Human Genome Science

    RHEUMATOID ARTHRITIS

    A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA) Roche 

    GOUT-Ardea Bioscience

    A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects with Tophaceous Gout

    A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor

    A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic  Response to Standard of Care Allopurinol

  • If you would like to participate in a clinical trial please contact:
    Francesca Madai:
     

    614-688-6296
    Francesca.madiai@osumc.edu

  • PubMed list of publications